ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has seen its stock price gain 1.48, or -4.92%, so far in 2017. In the past 3-month period alone, shares of ACAD have appreciated -8.28 – or -22.43%. The stock’s 52-week range is $25.06 to $41.20, and its 3-month range is $26.01 to $38.00.
The average Wall Street analyst rating for ACADIA Pharmaceuticals Inc. is Strong Buy, according to the average of 7 analyst scores. Of those analysts, 6 rate stock as a Strong Buy, 1 rate it as Hold, and just no analyst rates it as a Moderate Sell.Insider Trading Activity for ACADIA Pharmaceuticals Inc.
Looking at insider trading can give great insight into how ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is performing. ACADIA Pharmaceuticals Inc. has had 4 insider trades in the last 3 months, including 0 open market buys and 4 sells. Of those insider trades, 0 shares of ACADIA Pharmaceuticals Inc. were purchased and 156,719 shares were sold. The total number of shares traded in the last 90-day period is 156,719.
Insider trading over the last 12 months, however, paints a different picture. In the last year there have been a total of 15 insider trades, including 0 open market buys and 15 sells. Of those transactions, there were 0 shares of ACAD bought and 497,887 shares sold. The total number of shares traded in the last 12 months is 497,887.
The most recent open market insider trade was Automatic Sell of 25,000 shares on a day where the closing price was 30.06. The insider, BREGE LAURA, now holds 0 shares of ACAD.
The most recent non open market insider trade was completed by BAKER BROS. ADVISORS LP on 11/27/2017, and was a disposition of 1,941 shares with a final price of $28. The insider now holds 27.23 million shares of ACADIA Pharmaceuticals Inc. (ACAD).Examining Institutional Ownership at ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
According to ACADIA Pharmaceuticals Inc.’s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 96.80%. The total amount of shares outstanding is 121.89 million, giving the company a market capitalization of about 3.49 billion.
There are 234 institutional holders with active positions, accounting for 120.22 million shares in total. Of those holders, 102 had increased positions amounting to 6.85 million shares, 96 had decreased positions amounting to 8.88 million shares, and 36 holders have a held position accounting for 104.5 million shares.
The top 5 institutional holders, in ascending order, are as follows: BAKER BROS. ADVISORS LP with 25.82 million shares, FMR LLC with 18.36 million shares, VANGUARD GROUP INC with 7.77 million shares, BLACKROCK INC. with 6.39 million shares, and JANUS HENDERSON GROUP PLC with 5.96 million shares.
According to ACADIA Pharmaceuticals Inc. (ACAD) most recent 13F filing, the company has 33 new institutional holders – accounting for 1.03 million shares of its common stock. There were 24 sold out positions, amounting to 1.76 million shares.